Company news
Qiagen N.v. (NYSE:QGEN) news
Qiagen N.v. news releases on 6ix. Latest, Oct 6, 2026: QIAGEN Expands AI-Powered Bioinformatics for Research and Drug Discovery
Press releases & updates
QIAGEN Expands AI-Powered Bioinformatics for Research and Drug Discovery
October 6, 2026
QIAGEN Completes U.S. QIAstat-Dx Bloodstream Infection Portfolio With FDA Clearance of New Bacteria Detection Panel
September 28, 2026
QIAGEN Launches QIAmini to Automate Small-Batch Sample Preparation
September 24, 2026
QIAGEN Calls Extraordinary General Meeting for Appointment of Jonathan M. Pratt to Managing Board
September 18, 2026
QIAGEN Launches QIAsymphony Connect for Automated Clinical Nucleic Acid Extraction
August 27, 2026
QIAGEN Appoints Jonathan M. Pratt as Chief Executive Officer
August 24, 2026
Qiagen N : 2026 Annual Report 2026 IFRS Half Year Report
August 20, 2026
QIAGEN Receives U.S. FDA Clearance for First QIAstat-Dx Bloodstream Infection Panel
August 10, 2026
QIAGEN Exceeds Q2 2026 Outlook as Pillars Deliver Solid Sales Growth; Reaffirms Full-Year Outlook
August 5, 2026
QIAGEN Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora Outbreak
July 15, 2026
QIAGEN N.V. to Release Results for Q2 2026 and Hold Webcast
July 15, 2026
QIAGEN Expands QIAstat-Dx Bloodstream Infection Testing Menu in Europe
July 14, 2026
Qiagen N : announces adjustment of conversion price under its US$500,000,000 Convertible Bonds due 2031
July 7, 2026
Qiagen N : announces adjustment of conversion price under its US$750,000,000 Convertible Bonds due 2032
July 7, 2026
Qiagen N : announces adjustment of conversion price under its US$500,000,000 Convertible Bonds due 2027
July 7, 2026
QIAGEN Expands QIAcuity Gene Expression Portfolio to Accelerate Digital PCR Adoption Across Research and Biopharma
June 15, 2026
QIAGEN Supports Infectious Disease Research and Surveillance Efforts for Bundibugyo Ebolavirus Outbreak
May 28, 2026
QIAGEN launches QIA Agent, connecting AI-driven scientific guidance across Sample to Insight workflows
May 20, 2026
QIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIA
May 19, 2026
QIAGEN to Appoint Dr. Metin Colpan as Honorary Chairman of the Supervisory Board, Continue Governance Renewal and Propose Increased Returns at 2026 Annual General Meeting
May 12, 2026
QIAGEN Plans to Launch New Fully Automated Sample to Insight Workflow and an AI-Enabled Risk Stratification Tool to Advance QuantiFERON Latent TB Testing
May 7, 2026
QIAGEN Reports Full Results for Q1 2026
May 6, 2026
QIAGEN reports preliminary Q1 2026 results: achieves adjusted EPS outlook with mixed sales trends; updates full-year 2026 outlook
April 27, 2026
QIAGEN to Showcase New Sample to Insight Solutions for Complex Oncology Applications at AACR 2026
April 16, 2026
QIAGEN Expands Into Bloodstream Infection Syndromic Testing With New Rapid QIAstat-Dx Panel
April 14, 2026
Bruker Announces Appointment of Thierry Bernard to its Board of Directors
April 1, 2026
Parse Biosciences, a QIAGEN Company, Launches FFPE-compatible Barcoding Technology for Whole Transcriptome Single Cell Analysis
March 31, 2026
Qiagen Announces Form 20-F Annual Report Filing for 2025 Results
March 20, 2026
QIAGEN Highlights Newly Published Data Supporting Efficacy of QuantiFERON for TB Prevention
March 19, 2026
QIAGEN Receives U.S. Clearance for Gastrointestinal Panels on Fully Automated QIAstat-Dx Rise Syndromic Testing System
March 10, 2026
Parse Biosciences Launches Evercode Whole Transcriptome V4 With Shorter Workflow, Higher Sensitivity and Higher Cell Recovery
February 19, 2026
QIAGEN Exceeds Q4 2025 Outlook Driven by Growth Pillars
February 4, 2026
QIAGEN Showcases QIAsprint Connect High-Throughput Automation System for Labs Worldwide at SLAS 2026
February 3, 2026
QIAGEN Appoints Mark Stevenson to Supervisory Board
January 26, 2026
QIAGEN N.V. to Release Results for Q4 2025 and Hold Webcast
January 19, 2026
QIAGEN Sets 2026 Priorities to Drive Growth Across Five Pillars Toward Achieving 2028 Goals for Solid Profitable Growth
January 12, 2026
QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $500 Million
December 18, 2025
Oracle Names Stephen Rusckowski to the Board of Directors
November 19, 2025
QIAGEN Unveils QIAsymphony Connect and Showcases New Precision Oncology Innovations at AMP 2025
November 10, 2025
QIAGEN Exceeds Q3 2025 Outlook, Raises FY 2025 Adj. EPS Target, Announces Parse Acquisition and $500 Million Share Repurchase
November 4, 2025
QIAGEN to acquire Parse Biosciences, expanding its Sample technologies portfolio into highly scalable single-cell solutions
November 4, 2025
QIAGEN Launches New Automated Sexual Assault Sample Processing Kit at ISHI 2025
October 30, 2025
QIAGEN Marks 4,000th QIAcube Connect Placement, Reaffirming Leadership in Automated Sample Processing
October 28, 2025
QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast
October 13, 2025
QIAGEN Secures European CE-IVDR Certification for Full QIAstat-Dx Portfolio
September 10, 2025
QIAGEN Gains U.S. Clearance of Higher-Throughput QIAstat-Dx Rise, Expanding Patient Access to Rapid Syndromic Testing
September 2, 2025
QIAGEN N.V. Announces Conversion Price of New Net Share Settled Convertible Bonds
August 28, 2025
QIAGEN N.V. Announces Successful Placement of New Net Share Settled Convertible Bonds
August 28, 2025
QIAGEN N.V. Launches Non-US Offering of Net Share Settled Convertible Bonds
August 28, 2025
QIAGEN exceeds outlook for Q2 2025 with solid growth and improved profitability
August 5, 2025